Non-pregnancy group (N = 486) | Pregnancy group (N = 826) | P value | OR | P value | |
---|---|---|---|---|---|
Vaccination rate | 77% (357/461) | 84% (670/799) | 0.005 | 1.513 (1.134–2.019) | 0.005 |
Vaccination frequency | 0.002 | ||||
0 | 24% (113/471) | 16% (130/799) | Ref | ||
1 | 2% (11/471) | 2% (12/799) | 0.948 (0.403–2.232) | 0.903 | |
2 | 31% (147/471) | 30% (242/799) | 1.431 (1.034–1.98) | 0.031 | |
3 | 42% (199/471) | 52% (413/799) | 1.804 (1.332–2.444) | < 0.001 | |
4 | 0% (1/471) | 0% (2/799) | 1.738 (0.156–19.427) | 0.653 | |
Time from last vaccination to infection (days) | 385.2 (134.9) | 385.6 (126.6) | 0.8 | 1 (0.999–1.001) | 0.97 |
SARS-CoV-2 infection state | < 0.001 | ||||
0 (uninfected group) | 32% (157/486) | 32% (261/826) | Ref | ||
1 (diagnosed group) | 46% (222/486) | 55% (455/826) | 1.233 (0.956–1.591) | 0.107 | |
2 (suspected infection group) | 22% (107/486) | 13% (110/826) | 0.618 (0.444–0.862) | 0.005 | |
Time interval between embryo transfer and infection | 11.4 (6.2) | 12.4 (6.8) | 0.068 | 1.022 (1.001–1.043) | 0.042 |
SARS-CoV-2 infection symptoms | |||||
Fever and dizziness/headache | 29% (97/329) | 23% (130/565) | 0.032 | 0.715 (0.526–0.972) | 0.032 |
Fever and loss of appetite | 17% (55/329) | 17% (94/565) | > 0.9 | 0.994 (0.691–1.432) | 0.975 |
Dizziness/headache and loss of appetite | 13% (44/329) | 12% (68/565) | 0.6 | 0.886 (0.59–1.33) | 0.56 |